Adductor Canal Block for ACL Tear
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the drug Ropivacaine + Dexmedetomidine for ACL tear?
Is the combination of Ropivacaine and Dexmedetomidine safe for use in humans?
How does the adductor canal block differ from other treatments for ACL tear?
The adductor canal block for ACL tear is unique because it uses a combination of ropivacaine, a local anesthetic, and dexmedetomidine, an alpha-2 agonist, to provide pain relief while preserving muscle strength. This approach allows for effective pain management with a lower concentration of anesthetic, reducing potential side effects compared to other treatments.12347
What is the purpose of this trial?
The goal of this randomized controlled feasibility clinical trial is to assess the feasibility of conducting a randomized trial of adding a perioperative single-shot adductor canal block to standard of care general anesthesia compared to non-regional techniques in pediatric patients undergoing arthroscopic anterior cruciate ligament (ACL) reconstruction. The main clinical question it aims to answer is does ACB result in improved Quality of Recovery-15 questionnaire scores on postoperative day 2 , postoperative day 14, and postoperative day 42. Secondary questions this study will address are will use of a single-shot adductor canal block result in: less total opioid consumption; shorter post anesthetic care unit (PACU) length of stay; better pain scores at rest and with movement at time of postoperative phone call; and patient satisfaction score at 2 weeks (postoperative day 14). Researchers will compare the scores to patients undergoing the same surgery who will not have a single-shot ACB. All patients will receive the same pre-, peri-, and postoperative care with the exception of being randomized to block or no block. Participants will be asked to answer the Quality of Recovery-15 questionnaire and rate their pain on a scale of 0-10 on the day of surgery, at postoperative day 2 (by telephone) and at postoperative day 14 and postoperative day 42 during regular orthopedic clinic follow-up. Patients and caregivers will rate their satisfaction at postoperative day 42, using a 5-item Likert scale (ranging from completely dissatisfied to completely satisfied).
Eligibility Criteria
This trial is for pediatric patients needing ACL reconstruction surgery. Participants must be suitable for both general anesthesia and the specific nerve block being tested. The study excludes those with contraindications to the medications used or who cannot follow up.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Preoperative
Participants receive a standardized general anesthetic technique, with or without a single-shot adductor canal block
Postoperative Monitoring
Participants are monitored for pain management and recovery quality using the QoR-15 questionnaire at multiple timepoints
Follow-up
Participants are monitored for safety and effectiveness after treatment, including satisfaction and pain management assessments
Treatment Details
Interventions
- Ropivacaine + Dexmedetomidine
Find a Clinic Near You
Who Is Running the Clinical Trial?
Isabella Jaramillo
Lead Sponsor
McMaster University
Collaborator